BAVA Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

The transaction concerns the exercise of warrants by Thomas Bennekov, who has served as an employee-elected member of the Board of Directors of Bavarian Nordic since April 2021. The warrants were awarded to Mr. Bennekov in November 2019, prior to assuming his position on the Board.                 

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameThomas Bennekov
2.Reason for the notification
a)Position/statusEmployee-elected member of the Board of Directors of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Shares





DK0015998017
b)Nature of the transactionExercise of warrants
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 146.602,596
d)Aggregated information
  • Aggregated volume
  • Price
 



2,596

DKK 380,573.60
e)Date of the transaction2024-11-29
f)Place of the transactionNasdaq Copenhagen A/S, XCSE

About Bavarian Nordic

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, , Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 37 / 2024

Attachment



EN
29/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk...

Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk land Gentagen ordre fra unavngivet europæisk land til styrkelse af det offentlige beredskab.Sammen med andre nylige ordrer fra ikke-europæiske lande har selskabet nu sikret kontrakter for mere end DKK 3.000 mio. i Public Preparedness-forretningen i 2025, og rammer dermed det forventede interval for dette forretningsområde. KØBENHAVN, Danmark, 9. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har modtaget en kontrakt til en værdi på over DKK 200 mio. på levering af MVA-BN® koppe-/mpoxvaccine ti...

 PRESS RELEASE

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with ...

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000 million in contracts in the Public Preparedness business in 2025, thus entering the targeted guidance interval for this business. COPENHAGEN, Denmark, July 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a...

 PRESS RELEASE

Bavarian Nordic sælger Priority Review Voucher for USD 160 mio.

Bavarian Nordic sælger Priority Review Voucher for USD 160 mio. KØBENHAVN, Danmark, 18. juni 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 160 mio. kontant. Bavarian Nordic blev tildelt voucheren i februar 2025 i forbindelse med de amerikanske sundhedsmyndigheders godkendelse af chikungunyavaccinen VIMKUNYA™ til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. I henhold til en licensaftale, der blev overdraget til Bavarian Nordic i forbindelse med opkøbet af ...

 PRESS RELEASE

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 ...

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by chikungunya virus in people 12 years of age and older. Pursuant to a license agreement assumed upon acquisit...

 PRESS RELEASE

Indberetning af ledende medarbejdere og disses nærtståendes transaktio...

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer KØBENHAVN, Danmark, 9. maj 2025 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse, hvilke hermed offentliggøres i overensstemmelse med §19 i Europa Parlamentets og Rådets forordning (EU) nr. 596/2014 samt Kommissionens Gennemførelsesforordning (EU) nr. 2016/523. Transaktionerne vedrør...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch